Clinical trials
Phase 2 Heart Failure trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
56 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 3 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 7 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 42 |
| Terminated | 9 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Suspended | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bayer | 12 |
| Novartis Pharmaceuticals | 8 |
| AstraZeneca | 4 |
| University of Leipzig | 3 |
| Bristol-Myers Squibb | 2 |
| Cardurion Pharmaceuticals, Inc. | 2 |
| Medtronic Cardiac Rhythm and Heart Failure | 2 |
| Novo Nordisk A/S | 2 |
| ACS Biomarker | 1 |
| AskBio Inc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Heart Failure | 56 |
| Cardiovascular Diseases | 5 |
| Heart Diseases | 3 |
| Cardiomyopathy, Dilated | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Renal Insufficiency, Chronic | 2 |
| Cachexia | 1 |
| Cardiomegaly | 1 |
| Cardiomyopathies | 1 |
| Cheyne-Stokes Respiration | 1 |
Trials
Showing 1 to 25 of 56. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.